DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Erdheim-Chester disease — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleErdheim-Chester disease maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for erdheim-chester disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
B-Raf proto-oncogene, serine/threonine kinase (BRAF) — BRAF is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet agsdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8VYP · 3.29 Å · ligand PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER (AGS). Experimental structure, not a prediction.
What the evidence adds up to
Erdheim-Chester disease is a rare histiocytic disorder that can present as localised infiltration of foamy histiocytes or as a life-threatening multisystem disease. Fewer than 250 cases had been reported by 2012. In a 2023 international collaboration of 21 paediatric patients, childhood-onset ECD resembled the adult form, with similar molecular features and responses to agents targeting BRAF and MEK. A 2003 case report noted that the xanthoma-like lesions can cause significant morbidity and mortality.
A 2023 genome-wide association study of 255 ECD patients and 7,471 healthy donors identified the first germline genetic variant associated with the disease, with an odds ratio of 2.09. This association mapped to the SETBP1 gene, which is involved in clonal haematopoiesis. Functional annotation of this region and of suggestive signals revealed additional genes potentially involved in pathogenesis. The study demonstrated that germline genetic variants can impact ECD development.
A 2012 case report described a 16-year-old Malay male who initially presented with anaemic symptoms, with more specific symptoms of bone pain, cardiorespiratory and hepatic involvement evolving as the disease progressed. The 2003 report emphasised the need to familiarise clinicians with the disease and its differential diagnosis.
What remains missing are larger prospective paediatric cohorts to confirm the molecular and response patterns seen in the 21-patient study, and any trial that tests a specific drug regimen in a controlled fashion. The germline association requires replication in independent populations, and the functional role of the identified variants in disease initiation is not yet established. No trial design or patient stratification strategy has been validated for this rare disorder.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Blood · 2023 · 24 citations · open access
Childhood-onset Erdheim-Chester disease in the molecular era: clinical phenotypes and long-term outcomes of 21 patients
AbstractErdheim-Chester disease (ECD) is a rare histiocytic disorder that can present as a localized infiltration of foamy histiocytes or a multisystem disease that may be life-threatening. It is extremely rare in children. Pegoraro and colleagues present the clinical and molecular features of 21 patients with pediatric ECD through a large international collaboration, documenting that it resembles its adult counterpart, with similar molecular features and responses to agents targeting BRAF and MEK.
Journal of Cutaneous Medicine and Surgery · 2003 · 11 citations
Erdheim-Chester Disease
AbstractBACKGROUND: Erdheim-Chester disease is a rare non-Langerhans' cell histiocytosis. OBJECTIVE: This case report is presented to familiarize clinicians with Erdheim-Chester disease and its differential diagnosis. RESULTS AND CONCLUSION: Erdheim-Chester disease presents with unique clinical and pathologic findings. Its xanthoma-like lesions can cause significant morbidity and mortality.
<scp>Genome‐Wide</scp> Association Study Identifies the First Germline Genetic <scp>Variant Associated</scp> With <scp>Erdheim‐Chester</scp> Disease
AbstractOBJECTIVE: Erdheim-Chester disease (ECD) is rare histiocytosis with a wide range of clinical manifestations. Somatic mutations are key to the pathogenesis of the disease; however, the relationship between germline genetic variants and ECD has not been examined so far. The present study aims to explore the inherited genetic component of ECD by performing the first genome-wide association study. METHODS: After quality controls, a cohort of 255 patients with ECD and 7,471 healthy donors was included in this study. Afterward, a logistic regression followed by in silico functional annotation was performed. RESULTS: ; Odds Ratio = 2.09). This association was annotated to the SETBP1 gene, which is involved in clonal haematopoiesis. Functional annotation of this region and of the identified suggestive signals revealed additional genes that could be potentially involved in the pathogenesis of the disease. CONCLUSION: Overall, this work demonstrates that germline genetic variants can impact on the development of ECD and suggests new pathways with a potential pathogenic role.
AbstractABSTRACT: Erdheim-Chester disease (ECD) was first reported by J. Erdheim and W. Chester, in 1930. There are less than 250 reported cases till date. We report a case of ECD in a 16- year-old Malay male, who initially presented with elusive anemic symptoms with more specific symptoms of bony pain, cardiorespiratory and hepatic involvement evolving as the disease progressed. KEY WORDS: Erdheim-Chester disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
